FDA Delays Decision on Orexigen Obesity Pill by 3 Months

The FDA extended the review of Orexigen Therapeutics' (OREX) obesity pill Contrave by three months. Wednesday's expected approval decision is now pushed back to Sept. 11. 

"The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes for NB32," Orexigen said, in a statement. NB32 is Contrave. 

While the approval decision delay is a disappointment, it may work in Orexigen's favor if FDA allows cardiovascular outcomes data favorable to Contrave to be included in the weight loss drug's label. Orexigen's competitors Vivus (VVUS) and Arena Pharmaceuticals  (ARNA) lack data ruling out an increased risk of heart-related side effects. 


Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Legendary Technician Gives Her View of the Current Market

Legendary Technician Gives Her View of the Current Market

Jim Cramer: Be Careful in the Cannabis Stocks

Jim Cramer: Be Careful in the Cannabis Stocks

We Asked Our Pros About the Longevity of the Bull Market

We Asked Our Pros About the Longevity of the Bull Market

How Investors Can Profit by Focusing on This One Key Business Statistic

How Investors Can Profit by Focusing on This One Key Business Statistic

Want to Buy $1 Worth of Stock for 90 Cents or Less?

Want to Buy $1 Worth of Stock for 90 Cents or Less?